Eating the Dead to Keep Atherosclerosis at Bay

Frontiers in Cardiovascular Medicine

Volumn 4, Issue , 2017, Pages

  Brophy, Megan L ^a,b   Dong, Yunzhou ^b   Wu, Hao ^b   Rahman, H N Ashiqur ^b   Song, Kai ^b   Chen, Hong ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

apoptosis; atherosclerosis; autophagy; efferocytosis; macrophages

Indexed keywords

EID: 85019208265     PISSN: None     EISSN: 2297055X     Source Type: Journal    
DOI: 10.3389/fcvm.2017.00002     Document Type: Review

References (143)

1. Writing Group M Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation (2016) 133(4):e38–360.10.1161/CIR.0000000000000350
2. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med (2011) 17(11):1410–22.10.1038/nm.253822064431
3. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol (2012) 32(9):2045–51.10.1161/ATVBAHA.108.17970522895665
4. Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov (2011) 10(5):365–76.10.1038/nrd3444
5. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol (2006) 47(8 Suppl):C13–8.10.1016/j.jacc.2005.10.06516631505
6. Steinberg D. The LDL modification hypothesis of atherogenesis: an update. J Lipid Res (2009) 50(Suppl):S376–81.10.1194/jlr.R800087-JLR20019011257
7. Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially l-selectin dependent. J Exp Med (2006) 203(5):1273–82.10.1084/jem.2005220516682495
8. Zhao B, Li Y, Buono C, Waldo SW, Jones NL, Mori M, et al. Constitutive receptor-independent low density lipoprotein uptake and cholesterol accumulation by macrophages differentiated from human monocytes with macrophage-colony-stimulating factor (M-CSF). J Biol Chem (2006) 281(23):15757–62.10.1074/jbc.M51071420016606620
9. Buono C, Anzinger JJ, Amar M, Kruth HS. Fluorescent pegylated nanoparticles demonstrate fluid-phase pinocytosis by macrophages in mouse atherosclerotic lesions. J Clin Invest (2009) 119(5):1373–81.10.1172/JCI3554819363293
10. Barthwal MK, Anzinger JJ, Xu Q, Bohnacker T, Wymann MP, Kruth HS. Fluid-phase pinocytosis of native low density lipoprotein promotes murine M-CSF differentiated macrophage foam cell formation. PLoS One (2013) 8(3):e58054.10.1371/journal.pone.005805423536783
11. Kruth HS. Sequestration of aggregated low-density lipoproteins by macrophages. Curr Opin Lipidol (2002) 13(5):483–8.10.1097/00041433-200210000-0000312352011
12. Wentzel JJ, Corti R, Fayad ZA, Wisdom P, Macaluso F, Winkelman MO, et al. Does shear stress modulate both plaque progression and regression in the thoracic aorta? Human study using serial magnetic resonance imaging. J Am Coll Cardiol (2005) 45(6):846–54.10.1016/j.jacc.2004.12.02615766817
13. Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol (2007) 49(25):2379–93.10.1016/j.jacc.2007.02.05917599600
14. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis (1998) 139(2):205–22.10.1016/S0021-9150(98)00107-59712326
15. Papadopoulou C, Corrigall V, Taylor PR, Poston RN. The role of the chemokines MCP-1, GRO-alpha, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques. Cytokine (2008) 43(2):181–6.10.1016/j.cyto.2008.05.00918579408
16. Hopkins PN. Molecular biology of atherosclerosis. Physiol Rev (2013) 93(3):1317–542.10.1152/physrev.00004.201223899566
17. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol (2002) 15(6):439–46.10.1111/j.1540-8183.2002.tb01087.x12476646
18. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists’ view. Eur Heart J (2013) 34(10):719–28.10.1093/eurheartj/ehs41123242196
19. Cui D, Thorp E, Li Y, Wang N, Yvan-Charvet L, Tall AR, et al. Pivotal advance: macrophages become resistant to cholesterol-induced death after phagocytosis of apoptotic cells. J Leukoc Biol (2007) 82(5):1040–50.10.1189/jlb.030719217576822
20. Tabas I. Macrophage apoptosis in atherosclerosis: consequences on plaque progression and the role of endoplasmic reticulum stress. Antioxid Redox Signal (2009) 11(9):2333–9.10.1089/ARS.2009.246919243235
21. Ait-Oufella H, Horvat B, Kerdiles Y, Herbin O, Gourdy P, Khallou-Laschet J, et al. Measles virus nucleoprotein induces a regulatory immune response and reduces atherosclerosis in mice. Circulation (2007) 116(15):1707–13.10.1161/CIRCULATIONAHA.107.69947017875970
22. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation (1999) 99(3):348–53.10.1161/01.CIR.99.3.3489918520
23. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol (2010) 10(1):36–46.10.1038/nri267519960040
24. Vanden Berghe T, Kaiser WJ, Bertrand MJ, Vandenabeele P. Molecular crosstalk between apoptosis, necroptosis, and survival signaling. Mol Cell Oncol (2015) 2(4):e975093.10.4161/23723556.2014.97509327308513
25. O’Reilly E, Tirincsi A, Logue SE, Szegezdi E. The Janus face of death receptor signaling during tumor immunoediting. Front Immunol (2016) 7:446.10.3389/fimmu.2016.0044627843441
26. Justus SJ, Ting AT. Cloaked in ubiquitin, a killer hides in plain sight: the molecular regulation of RIPK1. Immunol Rev (2015) 266(1):145–60.10.1111/imr.1230426085213
27. Gautier EL, Huby T, Witztum JL, Ouzilleau B, Miller ER, Saint-Charles F, et al. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation (2009) 119(13):1795–804.10.1161/CIRCULATIONAHA.108.80615819307478
28. Imanishi T, Han DK, Hofstra L, Hano T, Nishio I, Liles WC, et al. Apoptosis of vascular smooth muscle cells is induced by Fas ligand derived from monocytes/macrophage. Atherosclerosis (2002) 161(1):143–51.10.1016/S0021-9150(01)00631-111882326
29. Timmins JM, Ozcan L, Seimon TA, Li G, Malagelada C, Backs J, et al. Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. J Clin Invest (2009) 119(10):2925–41.10.1172/JCI3885719741297
30. Karunakaran D, Geoffrion M, Wei L, Gan W, Richards L, Shangari P, et al. Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. Sci Adv (2016) 2(7):e1600224.10.1126/sciadv.160022427532042
31. Bjorkerud S, Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol (1996) 149(2):367–80.8701977
32. Kolodgie FD, Narula J, Burke AP, Haider N, Farb A, Hui-Liang Y, et al. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol (2000) 157(4):1259–68.10.1016/S0002-9440(10)64641-X11021830
33. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol (2005) 25(11):2255–64.10.1161/01.ATV.0000184783.04864.9f16141399
34. Bhatia VK, Yun S, Leung V, Grimsditch DC, Benson GM, Botto MB, et al. Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. Am J Pathol (2007) 170(1):416–26.10.2353/ajpath.2007.06040617200212
35. Thorp E, Tabas I. Mechanisms and consequences of efferocytosis in advanced atherosclerosis. J Leukoc Biol (2009) 86(5):1089–95.10.1189/jlb.020911519414539
36. Truman LA, Ford CA, Pasikowska M, Pound JD, Wilkinson SJ, Dumitriu IE, et al. CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood (2008) 112(13):5026–36.10.1182/blood-2008-06-16240418799722
37. Hochreiter-Hufford A, Ravichandran KS. Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harb Perspect Biol (2013) 5(1):a008748.10.1101/cshperspect.a00874823284042
38. Kinchen JM, Cabello J, Klingele D, Wong K, Feichtinger R, Schnabel H, et al. Two pathways converge at CED-10 to mediate actin rearrangement and corpse removal in C. elegans. Nature (2005) 434(7029):93–9.10.1038/nature0326315744306
39. Giles KM, Hart SP, Haslett C, Rossi AG, Dransfield I. An appetite for apoptotic cells? Controversies and challenges. Br J Haematol (2000) 109(1):1–12.10.1046/j.1365-2141.2000.01805.x
40. Krysko DV, Denecker G, Festjens N, Gabriels S, Parthoens E, D’Herde K, et al. Macrophages use different internalization mechanisms to clear apoptotic and necrotic cells. Cell Death Differ (2006) 13(12):2011–22.10.1038/sj.cdd.440190016628234
41. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell (2005) 123(2):321–34.10.1016/j.cell.2005.08.03216239148
42. Chung S, Gumienny TL, Hengartner MO, Driscoll M. A common set of engulfment genes mediates removal of both apoptotic and necrotic cell corpses in C. elegans. Nat Cell Biol (2000) 2(12):931–7.10.1038/3504658511146658
43. Miksa M, Amin D, Wu R, Ravikumar TS, Wang P. Fractalkine-induced MFG-E8 leads to enhanced apoptotic cell clearance by macrophages. Mol Med (2007) 13(11–12):553–60.10.2119/2007-00019.Miksa17673941
44. Spann NJ, Garmire LX, McDonald JG, Myers DS, Milne SB, Shibata N, et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell (2012) 151(1):138–52.10.1016/j.cell.2012.06.05423021221
45. Roszer T. Transcriptional control of apoptotic cell clearance by macrophage nuclear receptors. Apoptosis (2016).10.1007/s10495-016-1310-x27787652
46. A-Gonzalez N, Bensinger SJ, Hong C, Beceiro S, Bradley MN, Zelcer N, et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity (2009) 31(2):245–58.10.1016/j.immuni.2009.06.01819646905
47. Gerbod-Giannone MC, Li Y, Holleboom A, Han S, Hsu LC, Tabas I, et al. TNFalpha induces ABCA1 through NF-kappaB in macrophages and in phagocytes ingesting apoptotic cells. Proc Natl Acad Sci U S A (2006) 103(9):3112–7.10.1073/pnas.051034510316492740
48. Fond AM, Lee CS, Schulman IG, Kiss RS, Ravichandran KS. Apoptotic cells trigger a membrane-initiated pathway to increase ABCA1. J Clin Invest (2015) 125(7):2748–58.10.1172/JCI8030026075824
49. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature (1997) 390(6658):350–1.10.1038/37022
50. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest (1998) 101(4):890–8.10.1172/JCI11129466984
51. Reddy SM, Hsiao KH, Abernethy VE, Fan H, Longacre A, Lieberthal W, et al. Phagocytosis of apoptotic cells by macrophages induces novel signaling events leading to cytokine-independent survival and inhibition of proliferation: activation of Akt and inhibition of extracellular signal-regulated kinases 1 and 2. J Immunol (2002) 169(2):702–13.10.4049/jimmunol.169.2.70212097372
52. Korns D, Frasch SC, Fernandez-Boyanapalli R, Henson PM, Bratton DL. Modulation of macrophage efferocytosis in inflammation. Front Immunol (2011) 2:57.10.3389/fimmu.2011.0005722566847
53. Leitinger N, Schulman IG. Phenotypic polarization of macrophages in atherosclerosis. Arterioscler Thromb Vasc Biol (2013) 33(6):1120–6.10.1161/ATVBAHA.112.30017323640492
54. Schrijvers DM, De Meyer GR, Kockx MM, Herman AG, Martinet W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol (2005) 25(6):1256–61.10.1161/01.ATV.0000166517.18801.a715831805
55. Yancey PG, Blakemore J, Ding L, Fan D, Overton CD, Zhang Y, et al. Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation. Arterioscler Thromb Vasc Biol (2010) 30(4):787–95.10.1161/ATVBAHA.109.20205120150557
56. Yancey PG, Ding Y, Fan D, Blakemore JL, Zhang Y, Ding L, et al. Low-density lipoprotein receptor-related protein 1 prevents early atherosclerosis by limiting lesional apoptosis and inflammatory Ly-6Chigh monocytosis: evidence that the effects are not apolipoprotein E dependent. Circulation (2011) 124(4):454–64.10.1161/CIRCULATIONAHA.111.03226821730304
57. Kojima Y, Downing K, Kundu R, Miller C, Dewey F, Lancero H, et al. Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis. J Clin Invest (2014) 124(3):1083–97.10.1172/JCI7039124531546
58. Foks AC, Engelbertsen D, Kuperwaser F, Alberts-Grill N, Gonen A, Witztum JL, et al. Blockade of Tim-1 and Tim-4 enhances atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol (2016) 36(3):456–65.10.1161/ATVBAHA.115.30686026821944
59. Tao H, Yancey PG, Babaev VR, Blakemore JL, Zhang Y, Ding L, et al. Macrophage SR-BI mediates efferocytosis via Src/PI3K/Rac1 signaling and reduces atherosclerotic lesion necrosis. J Lipid Res (2015) 56(8):1449–60.10.1194/jlr.M05668926059978
60. Han J, Nicholson AC, Zhou X, Feng J, Gotto AM, Jr Hajjar DP. Oxidized low density lipoprotein decreases macrophage expression of scavenger receptor B-I. J Biol Chem (2001) 276(19):16567–72.10.1074/jbc.M01130220011278882
61. Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM, et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood (2007) 109(3):1026–33.10.1182/blood-2006-05-02163417047157
62. Driscoll WS, Vaisar T, Tang J, Wilson CL, Raines EW. Macrophage ADAM17 deficiency augments CD36-dependent apoptotic cell uptake and the linked anti-inflammatory phenotype. Circ Res (2013) 113(1):52–61.10.1161/CIRCRESAHA.112.30068323584255
63. Kojima Y, Volkmer JP, McKenna K, Civelek M, Lusis AJ, Miller CL, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature (2016) 536(7614):86–90.10.1038/nature1893527437576
64. Ghosh S. Early steps in reverse cholesterol transport: cholesteryl ester hydrolase and other hydrolases. Curr Opin Endocrinol Diabetes Obes (2012) 19(2):136–41.10.1097/MED.0b013e328350783622262001
65. Chistiakov DA, Bobryshev YV, Orekhov AN. Macrophage-mediated cholesterol handling in atherosclerosis. J Cell Mol Med (2016) 20(1):17–28.10.1111/jcmm.1268926493158
66. McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res (2011) 50(4):331–47.10.1016/j.plipres.2011.04.00221601592
67. Small DM. George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis (1988) 8(2):103–29.10.1161/01.ATV.8.2.1033348756
68. Tabas I. Apoptosis and plaque destabilization in atherosclerosis: the role of macrophage apoptosis induced by cholesterol. Cell Death Differ (2004) 11(Suppl 1):S12–6.10.1038/sj.cdd.4401444
69. Semple K, Nguyen A, Yu Y, Wang H, Anasetti C, Yu XZ. Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling. Blood (2011) 117(11):3096–103.10.1182/blood-2010-08-30127521245484
70. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature (2010) 464(7293):1357–61.10.1038/nature0893820428172
71. Li Y, Gerbod-Giannone MC, Seitz H, Cui D, Thorp E, Tall AR, et al. Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the Mer receptor. J Biol Chem (2006) 281(10):6707–17.10.1074/jbc.M51057920016380374
72. Feng B, Yao PM, Li Y, Devlin CM, Zhang D, Harding HP, et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol (2003) 5(9):781–92.10.1038/ncb103512907943
73. Shechtman CF, Henneberry AL, Seimon TA, Tinkelenberg AH, Wilcox LJ, Lee E, et al. Loss of subcellular lipid transport due to ARV1 deficiency disrupts organelle homeostasis and activates the unfolded protein response. J Biol Chem (2011) 286(14):11951–9.10.1074/jbc.M110.21503821266578
74. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol (2007) 8(7):519–29.10.1038/nrm219917565364
75. Todd DJ, Lee AH, Glimcher LH. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol (2008) 8(9):663–74.10.1038/nri235918670423
76. Chen X, Shen J, Prywes R. The luminal domain of ATF6 senses endoplasmic reticulum (ER) stress and causes translocation of ATF6 from the ER to the Golgi. J Biol Chem (2002) 277(15):13045–52.10.1074/jbc.M11063620011821395
77. Simionescu N, Vasile E, Lupu F, Popescu G, Simionescu M. Prelesional events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol (1986) 123(1):109–25.3963146
78. Gimbrone MA, Jr Garcia-Cardena G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res (2016) 118(4):620–36.10.1161/CIRCRESAHA.115.30630126892962
79. Davies PF, Civelek M, Fang Y, Fleming I. The atherosusceptible endothelium: endothelial phenotypes in complex haemodynamic shear stress regions in vivo. Cardiovasc Res (2013) 99(2):315–27.10.1093/cvr/cvt10123619421
80. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature (1997) 386(6620):73–7.10.1038/386073a09052782
81. Salvayre R, Auge N, Benoist H, Negre-Salvayre A. Oxidized low-density lipoprotein-induced apoptosis. Biochim Biophys Acta (2002) 1585(2–3):213–21.10.1016/S1388-1981(02)00343-812531556
82. Hong D, Bai YP, Gao HC, Wang X, Li LF, Zhang GG, et al. Ox-LDL induces endothelial cell apoptosis via the LOX-1-dependent endoplasmic reticulum stress pathway. Atherosclerosis (2014) 235(2):310–7.10.1016/j.atherosclerosis.2014.04.02824911634
83. Zhou J, Lhotak S, Hilditch BA, Austin RC. Activation of the unfolded protein response occurs at all stages of atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation (2005) 111(14):1814–21.10.1161/01.CIR.0000160864.31351.C115809369
84. Sanda GM, Deleanu M, Toma L, Stancu CS, Simionescu M, Sima AV. Oxidized LDL-exposed human macrophages display increased MMP-9 expression and secretion mediated by endoplasmic reticulum stress. J Cell Biochem (2016).10.1002/jcb.2563727341688
85. Sergin I, Razani B. Self-eating in the plaque: what macrophage autophagy reveals about atherosclerosis. Trends Endocrinol Metab (2014) 25(5):225–34.10.1016/j.tem.2014.03.01024746519
86. Shao BZ, Han BZ, Zeng YX, Su DF, Liu C. The roles of macrophage autophagy in atherosclerosis. Acta Pharmacol Sin (2016) 37(2):150–6.10.1038/aps.2015.8726750103
87. Boya P, Reggiori F, Codogno P. Emerging regulation and functions of autophagy. Nat Cell Biol (2013) 15(7):713–20.10.1038/ncb278823817233
88. Torisu K, Singh KK, Torisu T, Lovren F, Liu J, Pan Y, et al. Intact endothelial autophagy is required to maintain vascular lipid homeostasis. Aging Cell (2016) 15(1):187–91.10.1111/acel.1242326780888
89. Yang Q, Li X, Li R, Peng J, Wang Z, Jiang Z, et al. Low shear stress inhibited endothelial cell autophagy through TET2 downregulation. Ann Biomed Eng (2016) 44(7):2218–27.10.1007/s10439-015-1491-426493943
90. Ding Z, Liu S, Wang X, Khaidakov M, Dai Y, Mehta JL. Oxidant stress in mitochondrial DNA damage, autophagy and inflammation in atherosclerosis. Sci Rep (2013) 3:1077.10.1038/srep01077
91. Ding Z, Wang X, Schnackenberg L, Khaidakov M, Liu S, Singla S, et al. Regulation of autophagy and apoptosis in response to ox-LDL in vascular smooth muscle cells, and the modulatory effects of the microRNA hsa-let-7 g. Int J Cardiol (2013) 168(2):1378–85.10.1016/j.ijcard.2012.12.045
92. Martinet W, De Bie M, Schrijvers DM, De Meyer GR, Herman AG, Kockx MM. 7-ketocholesterol induces protein ubiquitination, myelin figure formation, and light chain 3 processing in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2004) 24(12):2296–301.10.1161/01.ATV.0000146266.65820.a115458974
93. Liao X, Sluimer JC, Wang Y, Subramanian M, Brown K, Pattison JS, et al. Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab (2012) 15(4):545–53.10.1016/j.cmet.2012.01.02222445600
94. Razani B, Feng C, Coleman T, Emanuel R, Wen H, Hwang S, et al. Autophagy links inflammasomes to atherosclerotic progression. Cell Metab (2012) 15(4):534–44.10.1016/j.cmet.2012.02.01122440612
95. Liu X, Tang Y, Cui Y, Zhang H, Zhang D. Autophagy is associated with cell fate in the process of macrophage-derived foam cells formation and progress. J Biomed Sci (2016) 23(1):57.10.1186/s12929-016-0274-z27473161
96. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, et al. Autophagy regulates lipid metabolism. Nature (2009) 458(7242):1131–5.10.1038/nature0797619339967
97. Avart SJ, Bernard DW, Jerome WG, Glick JM. Cholesteryl ester hydrolysis in J774 macrophages occurs in the cytoplasm and lysosomes. J Lipid Res (1999) 40(3):405–14.10064728
98. Ouimet M, Franklin V, Mak E, Liao X, Tabas I, Marcel YL. Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell Metab (2011) 13(6):655–67.10.1016/j.cmet.2011.03.02321641547
99. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr (2006) 83(2):456S–60S.16470012
100. Andreeva ER, Pugach IM, Orekhov AN. Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro. Atherosclerosis (1997) 135(1):19–27.10.1016/S0021-9150(97)00136-69395269
101. Matsumoto K, Hirano K, Nozaki S, Takamoto A, Nishida M, Nakagawa-Toyama Y, et al. Expression of macrophage (Mphi) scavenger receptor, CD36, in cultured human aortic smooth muscle cells in association with expression of peroxisome proliferator activated receptor-gamma, which regulates gain of Mphi-like phenotype in vitro, and its implication in atherogenesis. Arterioscler Thromb Vasc Biol (2000) 20(4):1027–32.10.1161/01.ATV.20.4.102710764668
102. Bentzon JF, Weile C, Sondergaard CS, Hindkjaer J, Kassem M, Falk E. Smooth muscle cells in atherosclerosis originate from the local vessel wall and not circulating progenitor cells in ApoE knockout mice. Arterioscler Thromb Vasc Biol (2006) 26(12):2696–702.10.1161/01.ATV.0000247243.48542.9d17008593
103. Allahverdian S, Chehroudi AC, McManus BM, Abraham T, Francis GA. Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Circulation (2014) 129(15):1551–9.10.1161/CIRCULATIONAHA.113.00501524481950
104. Feil S, Fehrenbacher B, Lukowski R, Essmann F, Schulze-Osthoff K, Schaller M, et al. Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis. Circ Res (2014) 115(7):662–7.10.1161/CIRCRESAHA.115.30463425070003
105. Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins RM, et al. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med (2015) 21(6):628–37.10.1038/nm.3866
106. Choi HY, Rahmani M, Wong BW, Allahverdian S, McManus BM, Pickering JG, et al. ATP-binding cassette transporter A1 expression and apolipoprotein A-I binding are impaired in intima-type arterial smooth muscle cells. Circulation (2009) 119(25):3223–31.10.1161/CIRCULATIONAHA.108.84113019528336
107. Allahverdian S, Pannu PS, Francis GA. Contribution of monocyte-derived macrophages and smooth muscle cells to arterial foam cell formation. Cardiovasc Res (2012) 95(2):165–72.10.1093/cvr/cvs09422345306
108. Lacolley P, Regnault V, Nicoletti A, Li Z, Michel JB. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res (2012) 95(2):194–204.10.1093/cvr/cvs13522467316
109. Yin YW, Liao SQ, Zhang MJ, Liu Y, Li BH, Zhou Y, et al. TLR4-mediated inflammation promotes foam cell formation of vascular smooth muscle cell by upregulating ACAT1 expression. Cell Death Dis (2014) 5:e1574.10.1038/cddis.2014.53525522268
110. Clarke MC, Talib S, Figg NL, Bennett MR. Vascular smooth muscle cell apoptosis induces interleukin-1-directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ Res (2010) 106(2):363–72.10.1161/CIRCRESAHA.109.20838919926874
111. May JM, Harrison FE. Role of vitamin C in the function of the vascular endothelium. Antioxid Redox Signal (2013) 19(17):2068–83.10.1089/ars.2013.520523581713
112. Wallert M, Schmolz L, Galli F, Birringer M, Lorkowski S. Regulatory metabolites of vitamin E and their putative relevance for atherogenesis. Redox Biol (2014) 2:495–503.10.1016/j.redox.2014.02.00224624339
113. He F, Zuo L. Redox roles of reactive oxygen species in cardiovascular diseases. Int J Mol Sci (2015) 16(11):27770–80.10.3390/ijms16112605926610475
114. Siti HN, Kamisah Y, Kamsiah J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vascul Pharmacol (2015) 71:40–56.10.1016/j.vph.2015.03.00525869516
115. Moser MA, Chun OK. Vitamin C and heart health: a review based on findings from epidemiologic studies. Int J Mol Sci (2016) 17(8):E1328.10.3390/ijms1708132827529239
116. Rashidi B, Hoseini Z, Sahebkar A, Mirzaei H. Anti-atherosclerotic effects of vitamins D and E in suppression of atherogenesis. J Cell Physiol (2016).10.1002/jcp.2573827966778
117. Patetsios P, Song M, Shutze WP, Pappas C, Rodino W, Ramirez JA, et al. Identification of uric acid and xanthine oxidase in atherosclerotic plaque. Am J Cardiol (2001) 88(2):188–191, A6.10.1016/S0002-9149(01)01621-611448423
118. Nishino T, Okamoto K, Eger BT, Pai EF, Nishino T. Mammalian xanthine oxidoreductase – mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J (2008) 275(13):3278–89.10.1111/j.1742-4658.2008.06489.x18513323
119. Kushiyama A, Okubo H, Sakoda H, Kikuchi T, Fujishiro M, Sato H, et al. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. Arterioscler Thromb Vasc Biol (2012) 32(2):291–8.10.1161/ATVBAHA.111.23455922095983
120. Nomura J, Busso N, Ives A, Matsui C, Tsujimoto S, Shirakura T, et al. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci Rep (2014) 4:4554.10.1038/srep0455424686534
121. Tian H, Liu Q, Qin S, Zong C, Zhang Y, Yao S, et al. Synthesis and cardiovascular protective effects of quercetin 7-O-sialic acid. J Cell Mol Med (2017) 21(1):107–120.10.1111/jcmm.12943
122. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem (2004) 279(33):34682–90.10.1074/jbc.M40299920015178689
123. Szeto HH, Schiller PW. Novel therapies targeting inner mitochondrial membrane – from discovery to clinical development. Pharm Res (2011) 28(11):2669–79.10.1007/s11095-011-0476-8
124. Hao S, Ji J, Zhao H, Shang L, Wu J, Li H, et al. Mitochondrion-targeted peptide SS-31 inhibited oxidized low-density lipoproteins-induced foam cell formation through both ROS scavenging and inhibition of cholesterol influx in RAW264.7 cells. Molecules (2015) 20(12):21287–97.10.3390/molecules20121976426633327
125. Olson KA, Beatty AL, Heidecker B, Regan MC, Brody EN, Foreman T, et al. Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts. Eur Heart J (2015) 36(48):3426–34.10.1093/eurheartj/ehv38526294790
126. Mei W, Xiang G, Li Y, Li H, Xiang L, Lu J, et al. GDF11 protects against endothelial injury and reduces atherosclerotic lesion formation in apolipoprotein E-null mice. Mol Ther (2016) 24(11):1926–38.10.1038/mt.2016.16027502608
127. Fredman G, Serhan CN. Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochem J (2011) 437(2):185–97.10.1042/BJ2011032721711247
128. Fredman G, Hellmann J, Proto JD, Kuriakose G, Colas RA, Dorweiler B, et al. An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat Commun (2016) 7:12859.10.1038/ncomms1285927659679
129. Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol (2009) 21(1):38–46.10.1016/j.coi.2009.01.00919230638
130. Joffre J, Potteaux S, Zeboudj L, Loyer X, Boufenzer A, Laurans L, et al. Genetic and pharmacological inhibition of TREM-1 limits the development of experimental atherosclerosis. J Am Coll Cardiol (2016) 68(25):2776–93.10.1016/j.jacc.2016.10.01528007141
131. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem (2001) 276(7):4588–96.10.1074/jbc.M00909320011092892
132. James AM, Cocheme HM, Smith RA, Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem (2005) 280(22):21295–312.10.1074/jbc.M50152720015788391
133. Oyewole AO, Birch-Machin MA. Mitochondria-targeted antioxidants. FASEB J (2015) 29(12):4766–71.10.1096/fj.15-27540426253366
134. Dashdorj A, Jyothi KR, Lim S, Jo A, Nguyen MN, Ha J, et al. Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines. BMC Med (2013) 11:178.10.1186/1741-7015-11-17823915129
135. Gioscia-Ryan RA, LaRocca TJ, Sindler AL, Zigler MC, Murphy MP, Seals DR. Mitochondria-targeted antioxidant (MitoQ) ameliorates age-related arterial endothelial dysfunction in mice. J Physiol (2014) 592(12):2549–61.10.1113/jphysiol.2013.26868024665093
136. Mercer JR, Yu E, Figg N, Cheng KK, Prime TA, Griffin JL, et al. The mitochondria-targeted antioxidant MitoQ decreases features of the metabolic syndrome in ATM±/ApoE-/- mice. Free Radic Biol Med (2012) 52(5):841–9.10.1016/j.freeradbiomed.2011.11.026
137. Dhanasekaran A, Kotamraju S, Kalivendi SV, Matsunaga T, Shang T, Keszler A, et al. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J Biol Chem (2004) 279(36):37575–87.10.1074/jbc.M40400320015220329
138. Zang QS, Sadek H, Maass DL, Martinez B, Ma L, Kilgore JA, et al. Specific inhibition of mitochondrial oxidative stress suppresses inflammation and improves cardiac function in a rat pneumonia-related sepsis model. Am J Physiol Heart Circ Physiol (2012) 302(9):H1847–59.10.1152/ajpheart.00203.201122408027
139. Yao X, Carlson D, Sun Y, Ma L, Wolf SE, Minei JP, et al. Mitochondrial ROS induces cardiac inflammation via a pathway through mtDNA damage in a pneumonia-related sepsis model. PLoS One (2015) 10(10):e0139416.10.1371/journal.pone.013941626448624
140. Karnewar S, Vasamsetti SB, Gopoju R, Kanugula AK, Ganji SK, Prabhakar S, et al. Mitochondria-targeted esculetin alleviates mitochondrial dysfunction by AMPK-mediated nitric oxide and SIRT3 regulation in endothelial cells: potential implications in atherosclerosis. Sci Rep (2016) 6:24108.10.1038/srep2410827063143
141. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O’Neill LA, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J (2007) 21(2):325–32.10.1096/fj.06-7227rev17267386
142. Fredman G, Kamaly N, Spolitu S, Milton J, Ghorpade D, Chiasson R, et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med (2015) 7(275):275ra220.10.1126/scitranslmed.aaa1065
143. Chung J, Shim H, Kim K, Lee D, Kim WJ, Kang DH, et al. Discovery of novel peptides targeting pro-atherogenic endothelium in disturbed flow regions – targeted siRNA delivery to pro-atherogenic endothelium in vivo. Sci Rep (2016) 6:25636.10.1038/srep2563627173134